The effect of glucagon on infusion cholangiography.

Evans AF, Whitehouse GH

Clinical radiology1 Sept 1979Cited by 4 (Europe PMC)

PMID466952DOI10.1016/s0009-9260(79)80180-4PepBankPUB-00466952

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In cholangiography series A, glucagon improved biliary system delineation compared with controls.
In plain wordsIn cholangiography series A, glucagon improved biliary tract visibility compared with controls.
Peptide
Glucagon
Outcome
IncreaseBiliary system delineation, series A
Study
n = 41
Comparator
Controls without glucagon
Outcome group
Biliary Imaging · Gastrointestinal
Studied dose
2 mg · intravenousAs given in this study (human).
Source sentences
Summary
Delineation of the biliary system was considered better in both series in those patients who received glucagon when compared with the controls.
3 context sentences(design, population, supporting numbers)
Summary · context
In series A, 41 patients had ioglycamide infusions at a rate of 0.2833 g min-1 over 1 h.
Summary · context
Two mg of intravenous glucagon was injected into alternate cases in both series A and B immediately after the first radiograph was taken at the completion of the ioglycamide infusion.
Summary · context
Two observers in each series than assessed the radiographic opacification of the biliary system without prior knowledge of which patients had received the glucagon.
Report a problemFND-0046695201
02HumanNon-randomized trialEfficacy outcome
In cholangiography series A, glucagon increased gallbladder opacification compared with controls.
In plain wordsIn cholangiography series A, glucagon increased gallbladder visibility compared with controls.
Peptide
Glucagon
Outcome
IncreaseGallbladder opacification, series A
Study
n = 41
Comparator
Controls without glucagon
Outcome group
Biliary Imaging · Gastrointestinal
Studied dose
2 mg · intravenousAs given in this study (human).
Source sentences
Summary
Gallbladder opacification was definitely increased in series A in those receiving glucagon, and a similar tendency was shown in series B.
3 context sentences(design, population, supporting numbers)
Summary · context
In series A, 41 patients had ioglycamide infusions at a rate of 0.2833 g min-1 over 1 h.
Summary · context
Two mg of intravenous glucagon was injected into alternate cases in both series A and B immediately after the first radiograph was taken at the completion of the ioglycamide infusion.
Summary · context
Two observers in each series than assessed the radiographic opacification of the biliary system without prior knowledge of which patients had received the glucagon.
Report a problemFND-0046695203
03HumanNon-randomized trialEfficacy outcome
In cholangiography series A, glucagon increased contrast in the upper intestine compared with controls.
In plain wordsIn cholangiography series A, glucagon increased upper intestinal contrast compared with controls.
Peptide
Glucagon
Outcome
IncreaseUpper intestinal contrast, series A
Study
n = 41
Comparator
Controls without glucagon
Outcome group
Biliary Imaging · Gastrointestinal
Studied dose
2 mg · intravenousAs given in this study (human).
Source sentences
Summary
The amount of contrast in the upper intestine was increased in series A in the glucagon group, but not in series B.
3 context sentences(design, population, supporting numbers)
Summary · context
In series A, 41 patients had ioglycamide infusions at a rate of 0.2833 g min-1 over 1 h.
Summary · context
Two mg of intravenous glucagon was injected into alternate cases in both series A and B immediately after the first radiograph was taken at the completion of the ioglycamide infusion.
Summary · context
Two observers in each series than assessed the radiographic opacification of the biliary system without prior knowledge of which patients had received the glucagon.
Report a problemFND-0046695205
04HumanNon-randomized trialEfficacy outcome
In cholangiography series B, glucagon improved biliary system delineation compared with controls.
In plain wordsIn cholangiography series B, glucagon improved biliary tract visibility compared with controls.
Peptide
Glucagon
Outcome
IncreaseBiliary system delineation, series B
Study
n = 31
Comparator
Controls without glucagon
Outcome group
Biliary Imaging · Gastrointestinal
Studied dose
2 mg · intravenousAs given in this study (human).
Source sentences
Summary
Delineation of the biliary system was considered better in both series in those patients who received glucagon when compared with the controls.
3 context sentences(design, population, supporting numbers)
Summary · context
In series B, 31 patients had ioglycamide infusions at a rate of 0.3886 g min-1 over 30 min.
Summary · context
Two mg of intravenous glucagon was injected into alternate cases in both series A and B immediately after the first radiograph was taken at the completion of the ioglycamide infusion.
Summary · context
Two observers in each series than assessed the radiographic opacification of the biliary system without prior knowledge of which patients had received the glucagon.
Report a problemFND-0046695202
05HumanNon-randomized trialEfficacy outcome
In cholangiography series B, glucagon showed a tendency toward increased gallbladder opacification compared with controls.
In plain wordsIn cholangiography series B, glucagon tended to increase gallbladder visibility compared with controls.
Peptide
Glucagon
Outcome
IncreaseGallbladder opacification, series B
Study
n = 31
Comparator
Controls without glucagon
Outcome group
Biliary Imaging · Gastrointestinal
Studied dose
2 mg · intravenousAs given in this study (human).
Source sentences
Summary
Gallbladder opacification was definitely increased in series A in those receiving glucagon, and a similar tendency was shown in series B.
3 context sentences(design, population, supporting numbers)
Summary · context
In series B, 31 patients had ioglycamide infusions at a rate of 0.3886 g min-1 over 30 min.
Summary · context
Two mg of intravenous glucagon was injected into alternate cases in both series A and B immediately after the first radiograph was taken at the completion of the ioglycamide infusion.
Summary · context
Two observers in each series than assessed the radiographic opacification of the biliary system without prior knowledge of which patients had received the glucagon.
Report a problemFND-0046695204
06HumanNon-randomized trialEfficacy outcome
In cholangiography series B, glucagon did not increase contrast in the upper intestine compared with controls.
In plain wordsIn cholangiography series B, glucagon did not increase upper intestinal contrast compared with controls.
Peptide
Glucagon
Outcome
No significant changeUpper intestinal contrast, series B
Study
n = 31
Comparator
Controls without glucagon
Outcome group
Biliary Imaging · Gastrointestinal
Studied dose
2 mg · intravenousAs given in this study (human).
Source sentences
Summary
The amount of contrast in the upper intestine was increased in series A in the glucagon group, but not in series B.
3 context sentences(design, population, supporting numbers)
Summary · context
In series B, 31 patients had ioglycamide infusions at a rate of 0.3886 g min-1 over 30 min.
Summary · context
Two mg of intravenous glucagon was injected into alternate cases in both series A and B immediately after the first radiograph was taken at the completion of the ioglycamide infusion.
Summary · context
Two observers in each series than assessed the radiographic opacification of the biliary system without prior knowledge of which patients had received the glucagon.
Report a problemFND-0046695206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.